Shajini
Synopulse’s NeuroPulse Daily tracks major movements across neurology, including new Parkinson’s diagnostics, ALS care funding, Huntington’s genetic medicine progress, AI-powered imaging clearance, breakthrough neurotechnology, and multimillion-dollar collaborations accelerating CNS drug discovery.
Valo Health has entered a collaboration with Merck KGaA, Darmstadt, Germany worth over $3 billion to accelerate AI-driven discovery of Parkinson’s disease therapies.
Minnesota applied for $1B under the federal Rural Health Transformation Program to strengthen rural hospitals, telehealth, and workforce capacity.
Alkermes has increased its offer to acquire Avadel to $22.50 per share, valuing the deal at up to $2.37 billion.
Today’s neurology roundup highlights momentum across Alzheimer’s and ALS drug development, spinal cord injury research, intravascular imaging, and next-gen MRI technologies.
Philips Debuts AI DeviceGuide to Enhance Real-Time Navigation in Heart Valve Repair
IQWiG has concluded that darolutamide offers no proven added benefit over apalutamide for metastatic hormone-sensitive prostate cancer.
NICE has issued three major recommendations expanding access to Columvi-GemOx for DLBCL, talquetamab for relapsed myeloma, and delgocitinib for chronic hand eczema.
Doctors providing check-ups with a sign announcing free annual health checks and expanded insurance. Vietnam Sets Ambitious 2026 Plan for Free Annual Health Checks, Expanded Coverage, and System-Wide Reform Vietnam is preparing to deliver one of its most far-reaching public-health reforms in decades, a nationwide guarantee of one free annual health check or screening for … Read more
Biogen has earned a positive CHMP opinion for its high-dose nusinersen regimen, supported by strong DEVOTE study results showing major motor improvements and reduced mortality risk in SMA patients.